PTPN11 - Wiki-Pi

Search Results for: PTPN11

Can't find the interaction you're looking for? Try the advanced search

174 interactions involving PTPN11 - protein tyrosine phosphatase non-receptor type 11 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases

Symbol	Description	Pathways Hide	Drugs Hide	Diseases Hide
IRS1	insulin receptor substrate 1	PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Signaling by ALK Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Activated NTRK3 signals through PI3K Signaling by ALK fusions and activated point mutants Growth hormone receptor signaling Signaling by LTK	[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
IRS2	insulin receptor substrate 2	PI3K Cascade IRS-mediated signalling SOS-mediated signalling SOS-mediated signalling PIP3 activates AKT signaling Interleukin-7 signaling PI3K/AKT activation PI3K/AKT activation Constitutive Signaling by Aberrant PI3K in Cancer IRS-related events triggered by IGF1R Signaling by Leptin RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation RET signaling Signaling by Erythropoietin Signaling by Erythropoietin Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Growth hormone receptor signaling
IRS4	insulin receptor substrate 4	IRS-related events triggered by IGF1R
JAK1	Janus kinase 1	Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation ISG15 antiviral mechanism Interleukin-7 signaling Interleukin-7 signaling Other interleukin signaling RAF/MAP kinase cascade Interleukin-10 signaling Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-15 signaling Interleukin-15 signaling Interleukin-35 Signalling Interleukin-9 signaling Interleukin-2 signaling Interleukin-12 signaling Interleukin-12 signaling Interleukin-27 signaling Interleukin-27 signaling Interleukin-21 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling Regulation of IFNA/IFNB signaling Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses IFNG signaling activates MAPKs Evasion by RSV of host interferon responses PD-L1(CD274) glycosylation and translocation to plasma membrane	Myricetin 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one Ruxolitinib Tofacitinib Baricitinib Fostamatinib Fedratinib Filgotinib Abrocitinib Upadacitinib Pralsetinib Ivarmacitinib
JAK2	Janus kinase 2	Interleukin-6 signaling Interleukin-6 signaling MAPK3 (ERK1) activation MAPK1 (ERK2) activation Prolactin receptor signaling Prolactin receptor signaling Signaling by SCF-KIT Signaling by Leptin RMTs methylate histone arginines Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF activation RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling IL-6-type cytokine receptor ligand interactions Signaling by moderate kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cyclin D associated events in G1 Interferon gamma signaling Regulation of IFNG signaling Regulation of IFNG signaling Interleukin-20 family signaling Interleukin-35 Signalling Signaling by Erythropoietin Signaling by Erythropoietin Interleukin-12 signaling Interleukin-12 signaling Interleukin-23 signaling Interleukin-23 signaling Interleukin-27 signaling Interleukin-27 signaling Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phosphoinositide-3-kinase (PI3K) Erythropoietin activates Phospholipase C gamma (PLCG) Erythropoietin activates STAT5 Erythropoietin activates RAS Erythropoietin activates RAS Interleukin receptor SHC signaling Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Potential therapeutics for SARS Inactivation of CSF3 (G-CSF) signaling Inactivation of CSF3 (G-CSF) signaling IFNG signaling activates MAPKs Growth hormone receptor signaling Growth hormone receptor signaling Factors involved in megakaryocyte development and platelet production	2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one XL019 5-phenyl-1H-indazol-3-amine 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM Ruxolitinib Tofacitinib Pacritinib Baricitinib Entrectinib Fostamatinib Fedratinib Abrocitinib Zanubrutinib Pralsetinib	Polycythemia vera
KDR	kinase insert domain receptor	Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization Integrin cell surface interactions VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated cell proliferation Signaling by membrane-tethered fusions of PDGFRA or PDGFRB High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Sorafenib Sunitinib 1-{4-[4-Amino-6-(4-methoxyphenyl)furo[2,3-d]pyrimidin-5-yl]phenyl}-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea Cediranib Vatalanib XL999 TG-100801 XL820 CYC116 Ramucirumab Pegdinetanib RAF-265 Linifanib IMC-1C11 Semaxanib Pazopanib Midostaurin Axitinib 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide N-(4-phenoxyphenyl)-2-[(pyridin-4-ylmethyl)amino]nicotinamide N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide 6-chloro-N-pyrimidin-5-yl-3-{[3-(trifluoromethyl)phenyl]amino}-1,2-benzisoxazole-7-carboxamide N-(CYCLOPROPYLMETHYL)-4-(METHYLOXY)-3-({5-[3-(3-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-YL}AMINO)BENZENESULFONAMIDE N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE 3-(2-aminoquinazolin-6-yl)-1-(3,3-dimethylindolin-6-yl)-4-methylpyridin-2(1H)-one 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one N'-(6-aminopyridin-3-yl)-N-(2-cyclopentylethyl)-4-methyl-benzene-1,3-dicarboxamide N~4~-methyl-N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Cabozantinib Regorafenib Ponatinib Lenvatinib Nintedanib Tivozanib Fostamatinib Erdafitinib Foretinib Ripretinib Pralsetinib Olinvacimab
KIR2DL5A	killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 5A
KIT	KIT proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Regulation of KIT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by extracellular domain mutants of KIT Transcriptional and post-translational regulation of MITF-M expression and activity Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Sorafenib Imatinib Dasatinib Sunitinib Phosphonotyrosine Nilotinib XL820 OSI-930 Linifanib Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Ancestim Tivozanib Fostamatinib Erdafitinib Amuvatinib Pexidartinib Ripretinib Avapritinib	Acute myeloid leukemia (AML) Piebaldism
KLRC1	killer cell lectin like receptor C1	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
LAIR1	leukocyte associated immunoglobulin like receptor 1	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Neutrophil degranulation
LCK	LCK proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Nef Mediated CD4 Down-regulation Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 Co-inhibition by PD-1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RHOH GTPase cycle Interleukin-2 signaling Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants FLT3 signaling through SRC family kinases	Dasatinib AP-22408 Staurosporine 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid Phosphoaminophosphonic Acid-Adenylate Ester 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine Ponatinib Nintedanib Fostamatinib Zanubrutinib Zotiraciclib	Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
LEPR	leptin receptor		Leptin Metreleptin
LIFR	LIF receptor subunit alpha	IL-6-type cytokine receptor ligand interactions RUNX1 regulates transcription of genes involved in interleukin signaling		Stuve-Wiedemann syndrome
LILRB4	leukocyte immunoglobulin like receptor B4	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
LINC01558	long intergenic non-protein coding RNA 1558
LINC02907	long intergenic non-protein coding RNA 2907
LNX1	ligand of numb-protein X 1	Antigen processing: Ubiquitination & Proteasome degradation
LRP1	LDL receptor related protein 1	Scavenging of heme from plasma Retinoid metabolism and transport	Antihemophilic factor, human recombinant Tenecteplase Coagulation Factor IX (Recombinant) Lanoteplase Von Willebrand factor human Coagulation Factor IX Human Lonoctocog alfa Moroctocog alfa
MAP3K4	mitogen-activated protein kinase kinase kinase 4		Fostamatinib
MAP3K5	mitogen-activated protein kinase kinase kinase 5	Oxidative Stress Induced Senescence Oxidative Stress Induced Senescence

Page 5 out of 9 pages